A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for 3 years, and describing the recurrence rate. The secondary objective is to study the operative rate, glucocorticoid utilization rate, treatment escalation rate, hospitalization rate and incidence of related complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis

NCT02922374

Acute Severe Colitis (ASC)

UNKNOWN PHASE1/PHASE2

Critical State of "Remission-Recurrence" of Ulcerative Colitis

NCT06694883

Ulcerative Colitis

RECRUITING

Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis

NCT05735665

Ulcerative Colitis Chronic Moderate Ulcerative Colitis Chronic Severe

UNKNOWN NA

Fecal Biomarker Study for Patients With Ulcerative Colitis

NCT00780507

Ulcerative Colitis

COMPLETED

The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis

NCT03151850

Ulcerative Colitis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Assess the health condition of patients for 1year, 2year,3year and analyze outcomes and complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prospective Study Ulcerative Colitis in Remission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTL group

control group

Colonoscope

Intervention Type COMBINATION_PRODUCT

take off specimen

EXP group

Colonoscope

Intervention Type COMBINATION_PRODUCT

take off specimen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colonoscope

take off specimen

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* sign informed consent before proceeding with any specific procedure.
* ages:14-75
* subjects were diagnosed with ulcerative colitis in written form. (written diagnosis should include at least one histopathological change).
* mucosal healing or histological remission has been achieved after medical treatment.

1. histological assessment is performed by 2 pathologists independently, and endoscopy have been independently evaluated by two endoscopic doctors.
2. prospective cohort study (3) definition of endoscopic mucosal healing: Baron score\<=1 and Mayo score\<=1 (4) definition of histological remission: Truelove/ Richards=1 and Geboes score\<3.0 (5) sampling methods: the terminal ileum, the ascending colon, the transverse colon, the descending colon, the sigmoid colon, and the rectum, the six parts were randomly taken specimen (at least 2 tissues each).
* data integrity: the research data include: 1) enteroscopy; 2) laboratory examination indicators: blood routine, erythrocyte sedimentation rate, C reaction protein, liver function, renal function, fecal calprotectin, 3) serum concentration of infliximab, antibody to infliximab.
* subjects were treated with the following treatment Mesalazine, glucocorticoid, immunosuppressive agent (azathioprine or thalidomide), biologics (infliximab) 7. subjects have the ability to answer the questionnaire

Exclusion Criteria

* The diagnosis is unclear
* Subjects with history of colectomy
* Subjects with history of cancerogenesis
* Subjects with severe liver disease, defined as child-pugh Grade B or Grade C
* Subjects with severe renal disease, defined as Estimated glomerular filtration rate\<30
* major cardiovascular events, such as stroke, myocardial infarction, or unstable angina, occurred within 3 months before enrollment.
* Subjects during pregnancy.
* alcohol or drug abuse
* poor compliance 10 Planners and investors

Minimum Eligible Age

14 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes